

For Immediate Release
www.bio.org

Press Contact: Erin Reese
202-962-9235
Investor Contact: John Craighead
202-962-6632

Exciting Therapeutic Advances of 2009 to Highlight Eleventh Annual BIO CEO & Investor Conference

Obesity, Hepatitis-C, Anemia, Gout, MS, and More to be Showcased

WASHINGTON, DC – (January 22, 2009) – The Biotechnology Industry Organization (BIO) today announced the selection of therapeutic workshops to be presented at the Eleventh Annual BIO CEO & Investor Conference, taking place February 9-10, 2009 at the Waldorf=Astoria Hotel in New York City. Experts chosen to speak on these panels represent leading clinical institutions, medical foundations, and public and private biotechnology companies.

“This year’s BIO CEO & Investor Conference will provide a unique forum to showcase therapeutic areas with key catalysts in 2009, from new and dynamic therapies to cutting edge investment opportunities,” said Alan Eisenberg, executive vice president of Emerging Companies & Business Development at BIO. “This conference provides the opportunity for industry executives and members of the investment community to meet, network, and address the challenges and solutions needed for the current market environment.”

The BIO CEO & Investor Conference’s therapeutic workshops will focus on topics addressing the latest developments in therapies for a wide range of diseases. This year’s therapeutic workshop topics include:

Metabolic: Feeding the Need for New Treatments in Obesity

Monday, February 9, 11am-12:10pm

Moderator: Liana Moussatos, PhD, Senior Healthcare Research Analyst, Pacific Growth Equities, LLC

Industry: Arena Pharmaceuticals, Inc.
Vivus, Inc.

Clinician: F. Xavier Pi-Sunyer, MD, MPH, Professor of Medicine at Columbia University College of Physicians and Surgeons and Professor of Applied Physiology at Columbia Teachers College

Nephrology: The Future of Anemia Management—Up-and-Coming Products to Stimulate an Anemic Market

Monday, February 9, 12:30-1:35pm

Moderator: Eric Schmidt, Ph.D, Managing Director, Cowen & Company, LLC

Industry: Affymax , Inc.
AMAG Pharmaceuticals, Inc.

Clinician: Steven Fishbane, MD, Professor of Medicine at the State University of New York at Stony Brook School of Medicine
Chaim Charytan, MD, Chief of the Renal Division at New York Hospital Medical Center of Queens

Infectious Disease: Reinforcements on the Way—A Surge of New Treatments to Combat HCV

Monday, February 9, 1:45-2:55pm

Moderator: Jason Kolbert, Managing Director, Research, ThinkEquity LLC

Industry: Anadys Pharmaceuticals, Inc.
Human Genome Sciences, Inc.

Clinician: Douglas T. Dieterich, MD, Professor of Medicine, Director of Outpatient Hepatology in the Division of Liver Diseases, and Director of CME in the Department of Medicine at Mount Sinai School of Medicine in New York, NY

Human Genetics: Unmet Needs are in the Genes— Treatments for Rare Genetic Disorders

Tuesday, Feb 10, 9:30-10:55am

Moderator: Geoff Porges, Senior Biotechnology Analyst, Sanford C. Bernstein & Co., LLC

Industry: Shire Human Genetic Therapies, Inc.

Clinician: Barbara Burton, Director, PKU Program; Professor of Pediatrics, Northwestern University's Feinberg School of Medicine
Chet Whitley, Professor, Gene Therapy Center, University of Minnesota

Autoimmune: Is the Jury Still Out on Gout?

Tuesday, February 10, 12:30-1:40pm

Moderator: Kimberly Lee, D.O., Senior Healthcare Research Analyst, Wedbush Morgan PG Life Sciences

Industry: Ardea Biosciences, Inc.
Regeneron Pharmaceuticals, Inc.

Clinician: Michael Becker, MD, Professor of Medicine in the Section of Rheumatology in the Department of Medicine, University of Chicago School of Medicine

Oncology: The Forecast for the Melanoma Market—Partly Sunny or Mostly Cloudy?

Tuesday, February 10, 12:30-1:35pm

Moderator: Mike King, Head of Healthcare & Senior Managing Director

Rodman & Renshaw, LLC

Industry: Medarex , Inc.

Synta Pharmaceuticals Corp.

Clinician: Gary K. Schwartz, MD, Chief, Melanoma and Sarcoma Service at
Memorial Sloan Kettering Cancer Center

Anna C. Pavlick, Assistant Professor of Medicine and Dermatology, NYU
School of Medicine

Neurology: Not in Vein—New Advances in Orally Available Treatments for MS

Tuesday, February 10, 1:45pm-2:55pm

Moderator: Mark Schoenbaum, MD, Managing Director-Senior Analyst
Biotechnology, Deutsche Bank Securities, Inc.

Clinician: Mark J. Tullman, M.D., Director of the Multiple Sclerosis Clinical Care
and Research Center at Columbia University Medical Center in New York
City

To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit <http://ceo.bio.org>. Registration is complimentary for qualified investors and credentialed members of the media.

Advance media registration is now available at
https://www.compusystems.com/servlet/ar?evt_uid=746&site=MEDIA.

The BIO CEO & Investor Conference is the largest independent investor conference focused solely on publicly-traded biotechnology companies. The meeting attracts institutional investors, industry analysts, and senior biotechnology executives. In addition, the BIO CEO & Investor Conference draws business development executives from leading global pharmaceutical and mature biotechnology companies.

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Upcoming BIO Events

[BIO CEO & Investor Conference 2009](#)

February 9-10, 2009
New York, New York

[BIO-Europe Spring](#)

March 16-18, 2009
Milan, Italy

[BIO IP Counsels' Committee Conference](#)

March 25-27, 2009
Phoenix, AZ

[BIO National Venture Conference](#)

March 31-April 1, 2009
Boston, MA

[BIO Windhover 2009](#)

April 13-15, 2009
New York, New York

[BIO-LES Business Development Basics Course](#)

May 15-17, 2009
Atlanta, GA

[BIO-LES Advanced Business Development Course](#)

May 15-17, 2009
Atlanta, GA

[BIO Executive Presentation Workshop](#)

May 17, 2009
Atlanta, GA

[2009 BIO International Convention](#)

May 18-21, 2009
Atlanta, Ga.

[BioEquity Europe](#)

June 9-10, 2009
Munich, Germany

[World Congress on Industrial Biotechnology & Bioprocessing](#)

July 19-22, 2009
Montreal, Quebec, Canada

###